SGLT2 Inhibitors in Cardiovascular Diseases
Mechanisms, Clinical Impact, and Future Directions
- 1st Edition - January 1, 2027
- Latest edition
- Editor: Tong Liu
- Language: English
SGLT2 Inhibitors in Cardiovascular Diseases: Mechanisms, Clinical Impact, and Future Directions reviews the impact of SGLT2 inhibitors on cardiovascular health in indivi… Read more
Description
Description
Key features
Key features
- Offers an in-depth review of the cardiovascular benefits of SGLT2 inhibitors, supported by both preclinical and clinical evidence
- Emphasizes the importance of comparing SGLT2 inhibitors with other diabetes medications, such as DPP4 inhibitors, to showcase their superior efficacy in reducing cardiovascular risks
- Explores less commonly discussed outcomes like atrial fibrillation and syncope
Readership
Readership
Table of contents
Table of contents
1. Overview of SGLT2 Inhibitors and Cardiovascular Disease
2. The Development of SGLT2 Inhibitors and Their Expanding Role in Cardiovascular Disease
Section II. Mechanisms of SGLT2 Inhibition in Cardiovascular Disease
3. Molecular Mechanisms of SGLT2 Inhibition in Cardiovascular Systems
4. SGLT2 Inhibition and Cardiovascular Pathophysiology
5. Impact of SGLT2 Inhibition on Cardiovascular Remodeling
Section III. Clinical Evidence and Applications
6. Cardiovascular Benefits of SGLT2 Inhibitors in Type 2 Diabetes
7. SGLT2 Inhibitors in Heart Failure
8. SGLT2 Inhibitors in Lipid Metabolism Disease. Focus on Atherosclerotic Cardiovascular
9. SGLT2 Inhibitors in Arrhythmias. Special Focus on Atrial Fibrillation and Syncope
10. SGLT2 Inhibitors vs. DPP4 Inhibitors in Cardiovascular Disease
11. SGLT2 Inhibitors in Cardiorenal and Metabolic Protection
Section IV. Efficacy and Safety of SGLT2 in Cardiovascular Diseases
12. Common Adverse Effects and Long-Term Safety
13. Efficacy and Safety in Special Populations
Section V. Future Directions and Unanswered Questions
14. Future Perspectives on SGLT2 Inhibitors in Cardiovascular Disease
15. Unanswered Questions and Ongoing Clinical Trials
Product details
Product details
- Edition: 1
- Latest edition
- Published: January 1, 2027
- Language: English
About the editor
About the editor
TL
Tong Liu
Tong Liu, MD, PhD, FESC, FHRS, ISNE-F, Youth Committee member of ISE, is a Professor of Cardiology at Tianjin Medical University and Deputy Director of the Tianjin Institute of Cardiology. With over 200 publications, he specializes in cardiac remodeling, arrhythmic disorders, and cardiovascular aging, and is on the Stanford Top 2% Scientists list. Dr. Liu leads research on biomarkers of cardiovascular aging and developing novel cardiac age models. He serves on the editorial boards of leading journals such as Pacing and Clinical Electrophysiology and BMC Cardiovascular Disorders and is Editor-in-Chief of Current Cardiology Reviews. His work focuses on molecular biology, clinical research, and the potential role of SGLT-2 inhibitors in cardiovascular disease. Dr. Liu has also authored and edited nine books, including AI Augmented ECG Technology from Springer. His extensive research and leadership make him a prominent figure in cardiovascular aging and translational cardiology.